ALLO Stock Overview
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Allogene Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.33 |
52 Week High | US$6.05 |
52 Week Low | US$2.18 |
Beta | 0.86 |
11 Month Change | -6.80% |
3 Month Change | -46.80% |
1 Year Change | -53.12% |
33 Year Change | -91.13% |
5 Year Change | -91.30% |
Change since IPO | -90.68% |
Recent News & Updates
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30Recent updates
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Allogene: Leading The Allogeneic CAR-T Space, Again
Apr 01Allogene: Lifting Of The Clinical Hold Will Be A Major Binary
Jan 12Shareholder Returns
ALLO | US Biotechs | US Market | |
---|---|---|---|
7D | -8.6% | -0.7% | 0.07% |
1Y | -53.1% | 10.2% | 20.7% |
Return vs Industry: ALLO underperformed the US Biotechs industry which returned 10% over the past year.
Return vs Market: ALLO underperformed the US Market which returned 20.7% over the past year.
Price Volatility
ALLO volatility | |
---|---|
ALLO Average Weekly Movement | 9.1% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ALLO's share price has been volatile over the past 3 months.
Volatility Over Time: ALLO's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 233 | David Chang | www.allogene.com |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia.
Allogene Therapeutics, Inc. Fundamentals Summary
ALLO fundamental statistics | |
---|---|
Market cap | US$486.47m |
Earnings (TTM) | -US$292.30m |
Revenue (TTM) | US$87.00k |
5,592x
P/S Ratio-1.7x
P/E RatioIs ALLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALLO income statement (TTM) | |
---|---|
Revenue | US$87.00k |
Cost of Revenue | US$214.94m |
Gross Profit | -US$214.85m |
Other Expenses | US$77.45m |
Earnings | -US$292.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.40 |
Gross Margin | -246,951.72% |
Net Profit Margin | -335,973.56% |
Debt/Equity Ratio | 0% |
How did ALLO perform over the long term?
See historical performance and comparison